Boston Scientific
Boston Scientific doesn’t have its own transcatheter mitral valve repair, but it has invested in companies that do have TMVR.
In March, an analyst’s report suggested that Boston Scientific could be eyeing a Neovasc buyout. Boston Scientific already acquired the company’s advanced biological tissue business with a 15% equity stake.
The company also invested in MValve a few years ago, but hasn’t made any moves to completely acquire.